Immuneering Corporation reported a net loss of $11.6 million, or $0.18 per share, for the fourth quarter of 2025, a significant improvement from the $18.1 million loss ($0.58 per share) recorded in the same period a year earlier. The company’s full‑year 2025 loss narrowed to $56.0 million, or $1.27 per share, compared with $61.0 million ($2.04 per share) in 2024. Revenue remained at $0 for the year, consistent with its status as a clinical‑stage biopharmaceutical company. Cash, cash equivalents, and marketable securities stood at $217.0 million as of December 31 2025, providing a runway that management projects will extend into 2029.
The company highlighted a 64% overall survival rate at 12 months in its Phase 2a trial of atebimetinib combined with modified gemcitabine/nab‑paclitaxel (mGnP) in first‑line pancreatic‑cancer patients. This figure far exceeds the 35% benchmark for standard care and represents a substantial therapeutic advance in a disease with limited options. The data cutoff for the analysis was December 15 2025, underscoring the timeliness of the results.
Immuneering confirmed that the first patient in its pivotal Phase 3 MAPKeeper 301 trial will be dosed in mid‑2026. The company has secured alignment with both the FDA and EMA on the trial design, positioning the study for regulatory approval pathways that could accelerate market access. The planned enrollment is expected to begin in the second half of 2026, with the first patient dose slated for the middle of the year.
"We also made rapid progress in preparation for our pivotal Phase 3 trial in first‑line pancreatic cancer patients, MAPKeeper 301, having secured alignment with both the FDA and EMA on our trial design, and we are on track to dose the first patient mid‑year. With cash runway expected into 2029, uniquely encouraging clinical data, and a solid pipeline, we are strongly positioned to deliver on our mission to help patients live longer and feel better," said CEO Ben Zeskind. Chief Medical Officer Igor Matushansky added, "Based on the exceptional data from the ongoing Phase 2a clinical trial of atebimetinib in combination with mGnP in first‑line pancreatic cancer, we believe atebimetinib has the potential to deliver extraordinary overall survival with both durability and tolerability, two patient‑centered essentials that oncologists have long struggled to balance."
The announcement also confirmed that Immuneering has paused development of its second candidate, envometinib, to concentrate resources on atebimetinib. The company’s focus on a single, high‑potential program is intended to streamline development timelines and maximize the likelihood of regulatory success. In addition to pancreatic cancer, atebimetinib is being evaluated in combination with Libtayo (cemiplimab) for first‑line RAS‑mutant non‑small‑cell lung cancer, with patient dosing expected in the second half of 2026. The company’s strong cash position and reduced R&D spend on envometinib support its ability to fund these expanded clinical efforts.
The Q4 earnings and trial data represent a pivotal milestone for Immuneering, reinforcing its financial foundation and accelerating the development of a potentially transformative therapy for pancreatic cancer and other MAPK‑driven malignancies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.